PLRZ
PolyrizonDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-23
Current thesis
The best bull argument is execution progress: company-source updates show CRO engagement, added U.S. sites, and a defined NASARIX study path, which could matter for a low-coverage development-stage name if it converts into trial initiation, enrollment, and later data.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
April 2026 financing brought approximately $3.5 million of gross proceeds but also added pre-funded warrants and common warrants, creating potential dilution and trading overhang. [#PR-2026-04-07]
Momentum
96
Value
46
Sentiment
4
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $9.00 · Bull $15.00 · Bear $5.00
Data freshness
Prices
As of 2026-07-23
Fundamentals
As of 2026-07-22 • Vendor: Data Vendor v1
Scores
As of 2026-07-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-23
Investment thesis
As of 2026-07-23
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Why
Momentum96 · Δ7d -
Value46 · Δ7d +0.0
Sentiment4 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
96
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
46
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.0
Sentiment
4
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 95.6 / Value 46.4 / Sentiment 3.9
Fundamentals (TTM)As of 2026-07-22
Fundamentals (TTM)
As of 2026-07-22
Market Cap
$29.99M
Beta
-
Shares Out
2.08M
P/E (TTM) · Derived
-6.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.55
Rev YoY
-
EPS YoY
-
Gross Margin
-
Op Margin
-
Net Debt
-$12.27M
Current Ratio
29.03
As of 2026-07-23 • Updated nightlySource: Internal modelMethodology